Premium
YKL40: a key modulator of the CF inflammatory response?
Author(s) -
Bouvet Guillaume F,
Bulka Olivia,
Coriati Adèle,
Massé Chantal,
Berthiaume Yves
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.937.10
Subject(s) - proinflammatory cytokine , peripheral blood mononuclear cell , context (archaeology) , medicine , biomarker , cystic fibrosis , immunology , pulmonary function testing , glycemic , inflammation , biology , insulin , in vitro , paleontology , biochemistry
YKL‐40 is a human circulating chitinase‐like protein and inflammatory biomarker whose levels are elevated in the blood serum of cystic fibrosis (CF) patients and CF patients with dysglycemia. We explored the effects of treatment with YKL‐40 on peripheral blood mononuclear cells (PBMC) isolated from the whole blood of 70 CF patients, in the context of the inflammatory gene response. The relative expressions of genes for both proinflammatory and immunosuppressive molecules in response to YKL‐40 treatment were quantified and analyzed in conjugation with biological characteristics obtained from each patient, including forced expiratory volume (FEV 1 %), a functional measure of pulmonary ability or disease progression, as well as sex and glycemic status. We found significant positive correlations between the expression of IL‐10 and TGF‐b in response to YKL‐40. Additionally, the FEV 1 % was found to be negatively correlated with IL‐10 expression. After analysis against sex and glycemic status, we found that a significant proportion of the FEV 1 % low /IL‐10 high group consisted of dysglycemic women. These correlations suggest that as the degree of pulmonary function decreases across patients, CF‐PBMC express IL‐10/TGF‐b gene response to YKL‐40, and that dysglycemic women with CF are more predisposed to developing this phenotype in response to elevated YKL‐40 in the peripheral blood. In addition to being a proinflammatory protein and a biological marker of disease evolution, YKL‐40 looks to act as a complex inflammatory modulator in CF. Support or Funding Information Cystic Fibrosis Canada